On April 9, 2026 Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, reported that management will participate in five upcoming investor conferences in the second quarter of 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
25th Annual Needham Virtual Healthcare Conference
Location: Virtual
Date: April 14th
Bank of America Healthcare Conference 2026
Location: Encore at the Wynn – Las Vegas, NV
Date: May 13th
H.C. Wainwright 4th Annual BioConnect Investor Conference
Location: Nasdaq – New York, NY
Date: May 19th
2026 Jeffries Global Healthcare Conference
Location: Marriott Marquis – New York, NY
Date: June 4th
Goldman Sachs 47th Annual Global Healthcare Conference
Location: Loews Miami Beach Hotel – Miami Beach, FL
Date: June10th
The Company may participate in a presentation or a fireside chat at these conferences. When available, a live webcast will be accessible under "Events & Presentations" in the Investors section of the Company’s website at www.fatetherapeutics.com. An archived replay of the webcast will be available for 30 days on the Company’s website following the event.
(Press release, Fate Therapeutics, APR 9, 2026, View Source [SID1234664266])